Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin.

Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, Shirao K, Okusaka T, Ueno H, Ikeda M, Watanabe N. · 2004

Read Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. by Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, Shirao K, Okusaka T, Ueno H, Ikeda M, Watanabe N. (2004) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2410050.txt.

Introduction

Matsumura and colleagues ran the first human trial of a micelle-packed cancer drug in 2004. The drug was doxorubicin, a potent but harsh chemotherapy agent, loaded into NK911, a carrier made of polymer micelles. These tiny spheres slip out of leaky tumor blood vessels and linger in tumors, a quirk called the EPR effect.

Twenty-three patients with solid tumors got the drug by infusion every three weeks, with doses rising by a fast-escalation plan. The main harm was a drop in white blood cells, severe at the top doses. The maximum tolerated dose settled at 67 milligrams per square metre of body surface, and 50 was set for the next trial phase. Blood levels of the carrier rose in step with dose. One patient with metastatic pancreatic cancer had a partial tumor shrinkage.

Catalog record

CREATORMatsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, Shirao K, Okusaka T, Ueno H, Ikeda M, Watanabe N.
YEAR2004
COLLECTIONPAPERS
FORMATTXT
FILE SIZE31 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2410050

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin By Y Matsumura, T Hamaguchi, T Ura, K Muro, Y Yamada, Y Shimada, K Shirao, T Okusaka, H Ueno, M Ikeda, N Watanabe Published in: British Journal of Cancer DOI: 10.1038/sj.bjc.6602204 ABSTRACT Abstract NK911 is a novel supramolecular nanocarrier designed for the enhanced delivery of doxorubicin (DXR) and is one of the successful polymer micelle systems to exhibit an efficient accumulation in solid tumours in mice. The purpose of this study was to define the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLTs) of NK911 and to evaluate its pharmacokinetic profile in man. NK911 was given intravenously to patients with solid tumours every 3 weeks using an infusion pump at a rate of 10 mg DXR equivalent min−1. The starting dose was 6 mg DXR equivalent m−2, and the dose was escalated according to the accelerated titration method. A total of 23 patients participated in this study. Neutropenia was the predominant haematological toxicity, and grade 3 or 4 neutropenia was observed at doses of 50 and 67 mg m−2. Common nonhaematological toxicities were mild alopecia, stomatitis, and anorexia. In the dose identification part of the study, DLTs were observed at a dose of 67 mg m−2 (grade 4 neutropenia lasting more than 5 days). Thus, this dosage level was determined to be the MTD. Infusion-related reactions were not observed in any cases. The C5 min and area under the concentration curve parameters of NK911 exhibited dose-dependent characteristics. Among the 23 patients, a partial response was obtained in one patient with metastatic pancreatic cancer. NK911 was well tolerated and produced only moderate nausea and vomiting at myelosuppressive dosages. The recommended phase II dose was determined to be 50 mg m−2 every 3 weeks. Keywords: DDS, pharmacokinetics, NK911, micelle, doxorubicin, EPR effect Agents categorised as drug delivery systems (DDSs) have been developed based on the characteristic macroscopic features of solid tumours, such as hypervascularity, an irregular vascular architecture, the presence of several vascular permeability factors stimulating extravasation within the cancer, and the relatively poor drainage of macromolecules and particulates from cancer tissue. These characteristics, which are unique to solid tumours, constitute the basis of the enhanced permeability and retention (EPR) effect (Matsumura and Maeda, 1986; Maeda et al, 2000). Macromolecules have long plasma half-lives because they are too large to pass through normal vessel walls unless they are trapped by the reticuloendothelial system (RES) in the cells of various organs. Such macromolecular agents can diffuse out of tumour blood vessels, reach the solid tumour tissue, and be retained for a long period because of the EPR effect. To maximise the EPR effect, several techniques have been developed to modify the structures of drugs and to construct drug carriers. Doxil is comprised of doxorubicin (DXR) encapsulated in STEALTH™ liposomes, which are composed of a phospholipid bilayer with surface-bound methoxypolyethyleneglycol. Doxil recently received the US Food and Drug Administration’s (FDA) approval for use in the treatment of Kaposi sarcoma or ovarian cancer after the clinical benefits of this drug were clearly shown in recent clinical trials (Muggia et al, 1996; Stewart et al, 1998; Gordon et al, 2001). Polymeric micelles have also been utilised as a drug carrier system. The original form of micellar DXR contained two trapped components: a DXR monomer and a DXR dimer in the inner core (Yokoyama et al, 1990a, 1990b). However, the lyophilised micelle containing DXR dimers became insoluble after long periods of storage. To improve the solubility of this drug carrier system, a new type of polymeric micelle containing only the DXR monomer, known as NK911, has been developed (Nakanishi et al, 2001). The DXR monomers, rather than the DXR dimers, were thought to play a major role in the antitumour activity of the original micellar DXR drug preparation. The DXR dimers, on the other hand, were thought to stabilise the drug’s conformation. Thus, NK911, which only contains DXR monomers, is less stable in aqueous media than the original form of micellar DXR (Nakanishi et al, 2001; Tsukioka et al, 2002). Both polyethyleneglycol (PEG)-liposomal and micellar DXR have longer plasma half-lives, accumulate in tumours more effectively because of the EPR effect, and exhibit a stronger antitumour activity than free DXR when administered in mice. Both the plasma area under the concentration–time curve (AUC) and the tumour AUC of NK911 are, however, lower than those of doxil because NK911 is less stable in the bloodstream than doxil (Working et al, 1994; Nakanishi et al, 2001). At this stage, however, we have no definitive idea as to which formulation exerts a superior antitumour activity in vivo because an evaluation of the activity in vivo cannot be based solely on the enhanced tumour AUC; several additional factors, including the efficiency of the free drug inside the formulation and the distribution of the free drug throughout the tumour tissue, must also be taken into consideration. Proper selection of the type of DDS formulation is likely to depend on the tumour vessel density of the tumour tissue. With this in mind, we conducted a phase I clinical trial on the use of NK911 in patients with solid tumours. The study was performed at the National Cancer Center Hospital, Tokyo, Japan. Our objectives were to assess the safety and toxicity profile of NK911 and to determine the maximum-tolerated dose (MTD), the phase II recommended dose, and the pharmacokinetics of NK911 in man. PATIENTS AND METHODS The study protocol was reviewed and approved by the Institutional Review Board of the National Cancer Center, Tokyo. Therapeutic agent Figure 1 shows the schematic structure of NK911, a DXR-entrapped polymeric micelle formulation. The polymeric micelle consists of a PEG–poly(aspartic acid) block copolymer conjugated with DXR. Polyethyleneglycol is believed to form the outer shell of the micelle, producing a ‘stealth’ effect that prevents NK911 from being captured by the RES. The DXR-conjugated poly(aspartic acid) chain is hydrophobic and is believed to form the hydrophobic inner core of the micelles in aqueous media. The hydrophobic inner core enables NK911 to entrap a sufficient amount of DXR. NK911 has a diameter of about 40 nm (Nakanishi et al, 2001). [Figure: Schematic structure of NK911. A polymeric micelle carrier of NK911 consists of a block copolymer of PEG (molecular weight of about 5000) and poly(aspartic acid) (about 30 units). Polyethyleneglycol is believed to be the outer shell of the micelle. NK911 has a highly hydrophobic inner core, and therefore can entrap sufficient amounts of DXR.] Patients Patients with metastatic or recurrent solid tumours refractory to conventional chemotherapy and for whom no effective therapy was available were eligible for enrolment in this study, provided that the following criteria were met: a histologically confirmed malignant tumour; a performance status of ⩽2; an age of ⩾20 and <75 years; a normal haematological profile (neutrophil count ⩾2000 μl−1, platelet count ⩾100 000 μl−1, haemoglobin ⩾8 g dl−1); normal hepatic function (total bilirubin level ⩽1.5 mg dl−1, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ⩽2.5 times the upper normal limit); normal renal function (serum creatinine ⩽1.5 mg dl−1); normal cardiac function (New York Heart Association (NYHA) classification of ⩽1); normal pulmonary function (PaO2 ⩾60 mgHg); no chemotherapy within 4 weeks (6 weeks for nitrosourea or mitomycin

Read the complete text